Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07105215 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 6 to 39v3
  2. Trial status: Not Yet Recruiting to Recruiting Start date: Sep 30, 2025 to Aug 11, 2025 · Site details revised at 6 of 6 sitesv2 Show 2 more changesShow less
    • Start date: Sep 30, 2025 to Aug 11, 2025
    • Site details revised at 6 of 6 sites
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary objective is to evaluate the safety and tolerability of RC278; determine the maximum tolerated dose (MTD) and/or maximum administered dose (MAD) of RC278; and determine the recommended phase 2 dose (RP2D)， and assess the efficacy of RC278 at the RP2D dose;
Trial Details
NCT Number NCT07105215
Lead Sponsor RemeGen Co., Ltd.
Conditions Solid Tumors
Enrollment 312 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov